{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:36:51Z","timestamp":1786549011386,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The clinical benefit of simvastatin as an adjunctive treatment in liver cirrhosis remains inconclusive, with prior syntheses becoming outdated after the publication of the largest trial on the topic. This updated meta-analysis aimed to evaluate the therapeutic impact of simvastatin in cirrhotic patients. A systematic search was conducted in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov using MeSH terms related to \u201cSimvastatin\u201d and \u201cLiver Cirrhosis.\u201d Randomized controlled trials (RCTs) comparing simvastatin to placebo or any other drugs were included. Nine RCTs, including 966 patients, were analyzed. Simvastatin showed no statistically significant effect on all-cause mortality, although a borderline trend toward a 37% relative risk reduction was observed [risk ratio (RR): 0.63; 95% confidence interval (CI): 0.38\u20131.04;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.07], suggesting a potentially clinically meaningful effect. No significant differences were found in bleeding (RR: 0.70; 95% CI: 0.45\u20131.08), development of ascites (RR: 0.91; 95% CI: 0.69\u20131.21), hepatorenal syndrome (RR: 0.85; 95% CI: 0.64\u20131.87), hepatic venous pressure gradient (standardized mean difference [SMD]: \u22120.19; 95% CI: \u22120.49 to 0.11), wedged hepatic venous pressure (SMD: \u22120.11; 95% CI: \u22120.44 to 0.23), free hepatic venous pressure (SMD: 0.04; 95% CI: \u22120.21 to 0.29), and adverse events (RR: 1.04; 95% CI: 0.95\u20131.15), serious adverse events (RR: 0.93; 95% CI: 0.75\u20131.15), and musculoskeletal adverse events (RR: 1.27; 95% CI: 0.87\u20131.85). Overall, simvastatin did not demonstrate statistically significant reductions in cirrhosis-related complications. Nevertheless, the observed trend toward lower mortality suggests a possible protective effect that existing trials may be underpowered to confirm. Larger, well-designed RCTs are warranted to clarify its impact on survival outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005302","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:00:32Z","timestamp":1785258032000},"page":"5327-5338","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of simvastatin as adjunctive therapy in liver cirrhosis: an updated meta-analysis of randomized controlled trials"],"prefix":"10.1097","volume":"88","author":[{"given":"Muhammad Fahad","family":"Iqbal Khan","sequence":"first","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Afridi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Haris Khan","sequence":"additional","affiliation":[{"name":"Department of Accident and Emergency, Distric Head Quarters Hospital, Dera Ismail Khan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Zahid Anwar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Lady Reading Hospital, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nawaz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lady Reading Hospital, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umama","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pak International Medical College, Hyatabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Usama Nawaz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Saidu Medical College, Swat, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik","family":"Sheheryar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lady Reading Hospital, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hamad Ali","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Lady Reading Hospital, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Siddique Karimi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Saidu Teaching Hospital, Swat, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber College of Dentistry, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ayub Medical College, Abbotabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Faraz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sefatullah","family":"Sahak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Nangarhar University, Jalalabad, Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"R1-20260812","doi-asserted-by":"crossref","first-page":"e0026","DOI":"10.1097\/HC9.0000000000000026","article-title":"The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2019","volume":"7","author":"Lan","year":"2023","journal-title":"Hepatol Commun"},{"key":"R2-20260812","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12889-024-17948-6","article-title":"Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019","volume":"24","author":"Wu","year":"2024","journal-title":"BMC Public Health"},{"key":"R3-20260812","doi-asserted-by":"crossref","first-page":"2252326","DOI":"10.1080\/07853890.2023.2252326","article-title":"Changing epidemiology of cirrhosis from 2010 to 2019: results from the global burden disease study 2019","volume":"55","author":"Xiao","year":"2023","journal-title":"Ann Med"},{"key":"R5-20260812","doi-asserted-by":"crossref","first-page":"50\u201357","DOI":"10.1097\/CLD.0000000000000015","article-title":"Review of the role of statins in cirrhosis and portal hypertension","volume":"22","author":"Gratac\u00f3s-gin\u00e8s","year":"2023","journal-title":"Clin Liver Dis"},{"key":"R6-20260812","article-title":"Current views and prospects relating to the use of statins in patients with chronic liver disease and cirrhosis","volume":"10","author":"Reddy","year":"2025","journal-title":"Indian J Pharm Pharmacol"},{"key":"R7-20260812","doi-asserted-by":"crossref","first-page":"e0456","DOI":"10.1097\/HC9.0000000000000456","article-title":"Statin the course: navigating unchartered territory in cirrhosis","volume":"8","author":"Kezer","year":"2024","journal-title":"Hepatol Commun"},{"key":"R8-20260812","doi-asserted-by":"crossref","first-page":"1032\u201346","DOI":"10.1016\/j.jceh.2023.05.002","article-title":"Statins in cirrhosis: hope or hype?","volume":"13","author":"Shaffer","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"R9-20260812","doi-asserted-by":"crossref","first-page":"1\u201312","DOI":"10.14740\/gr1498","article-title":"Statin use in patients with chronic liver disease and cirrhosis: current evidence and future directions","volume":"15","author":"Kreidieh","year":"2022","journal-title":"Gastroenterol Res"},{"key":"R10-20260812","doi-asserted-by":"crossref","first-page":"97\u201397","DOI":"10.21037\/dmr-20-55","article-title":"Statins in patients with cirrhosis: a note of caution in the middle of hope","volume":"3","author":"Pereira","year":"2020","journal-title":"Dig Med Res"},{"key":"R11-20260812","doi-asserted-by":"crossref","first-page":"226\u201340","DOI":"10.1007\/s11938-018-0180-4","article-title":"The use of statins in patients with chronic liver disease and cirrhosis","volume":"16","author":"Moctezuma-vel\u00e1zquez","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"R12-20260812","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12876-019-1147-1","article-title":"Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"R13-20260812","doi-asserted-by":"crossref","first-page":"e0332","DOI":"10.1097\/HC9.0000000000000332","article-title":"Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial","volume":"7","author":"Kronborg","year":"2023","journal-title":"Hepatol Commun"},{"key":"R14-20260812","first-page":"108\u201320","article-title":"Effects of statins on the hepatic decompensation, mortality, complications and drug safety in liver cirrhosis: a systematic review and meta-analysis","volume":"6","author":"Tantai","year":"2018","journal-title":"Am J Intern Med"},{"key":"R15-20260812","doi-asserted-by":"crossref","first-page":"864\u201374","DOI":"10.1001\/jama.2024.27441","article-title":"Simvastatin and rifaximin in decompensated cirrhosis: a randomized clinical trial","volume":"333","author":"Pose","year":"2025","journal-title":"JAMA"},{"key":"R16-20260812","doi-asserted-by":"crossref","first-page":"140\u201354","DOI":"10.1097\/HEP.0000000000001148","article-title":"Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to \u03b2-blockers: a double-blind, placebo-controlled, randomized trial","volume":"82","author":"Alvarado-tapias","year":"2025","journal-title":"Hepatology"},{"key":"R17-20260812","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R19-20260812","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R20-20260812","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R21-20260812","doi-asserted-by":"crossref","first-page":"1106\u201310","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"R22-20260812","doi-asserted-by":"crossref","first-page":"020\u20136","DOI":"10.29328\/journal.acgh.1001010","article-title":"Addition of simvastatin to carvedilol and endoscopic variceal ligation improves rebleeding and survival in patients with Child-Pugh A and B class but not in Child Pugh C class","volume":"3","author":"Jha","year":"2019","journal-title":"Ann Clin Gastroenterol Hepatol"},{"key":"R23-20260812","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"R24-20260812","doi-asserted-by":"crossref","first-page":"256","DOI":"10.12688\/f1000research.13915.1","article-title":"Evaluation of portal pressure by doppler ultrasound in patients with cirrhosis before and after simvastatin administration - a randomized controlled trial","volume":"7","author":"Elwan","year":"2018","journal-title":"F1000Res"},{"key":"R25-20260812","doi-asserted-by":"crossref","first-page":"729\u201337","DOI":"10.14309\/ajg.0000000000000551","article-title":"Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial","volume":"115","author":"Vijayaraghavan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R26-20260812","doi-asserted-by":"crossref","first-page":"749\u201355","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"key":"R27-20260812","doi-asserted-by":"crossref","first-page":"1651\u201358","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"R28-20260812","first-page":"957\u201363","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-flores","year":"2015","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"R29-20260812","first-page":"388\u201398","article-title":"Global epidemiology of cirrhosis - aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R30-20260812","doi-asserted-by":"crossref","first-page":"517\u201321","DOI":"10.1016\/j.atherosclerosis.2008.12.023","article-title":"Statins inhibit rho kinase activity in patients with atherosclerosis","volume":"205","author":"Nohria","year":"2009","journal-title":"Atherosclerosis"},{"key":"R31-20260812","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/nu14030716","article-title":"Simvastatin Improves microcirculatory function in nonalcoholic fatty liver disease and downregulates oxidative and ALE-RAGE stress","volume":"14","author":"Pereira","year":"2022","journal-title":"Nutrients"},{"key":"R32-20260812","doi-asserted-by":"crossref","first-page":"449\u201358","DOI":"10.1042\/CS20110259","article-title":"Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries","volume":"121","author":"Rossoni","year":"2011","journal-title":"Clin Sci"},{"key":"R33-20260812","doi-asserted-by":"crossref","first-page":"4639\u201352","DOI":"10.3748\/wjg.v27.i28.4639","article-title":"Addition of statins to the standard treatment in patients with cirrhosis: safety and efficacy","volume":"27","author":"Mu\u00f1oz","year":"2021","journal-title":"World J Gastroenterol"},{"key":"R34-20260812","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1097\/MCG.0000000000001732","article-title":"Simvastatin is efficacious in treating cirrhosis: a meta-analysis","volume":"56","author":"Zhang","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"R35-20260812","doi-asserted-by":"crossref","first-page":"17\u201320","DOI":"10.1016\/S1567-5688(01)00010-1","article-title":"Immunosuppressive effects of statins","volume":"3","author":"Mach","year":"2002","journal-title":"Atheroscler"},{"key":"R36-20260812","doi-asserted-by":"crossref","first-page":"1564\u201377","DOI":"10.1053\/j.gastro.2018.07.022","article-title":"Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension","volume":"155","author":"Tripathi","year":"2018","journal-title":"Gastroenterology"},{"key":"R37-20260812","doi-asserted-by":"crossref","first-page":"293\u201399","DOI":"10.4254\/wjh.v9.i6.293","article-title":"Hepatorenal syndrome: update on diagnosis and therapy","volume":"9","author":"Acevedo","year":"2017","journal-title":"World J Hepatol"},{"key":"R38-20260812","doi-asserted-by":"crossref","first-page":"e030038","DOI":"10.1136\/bmjopen-2019-030038","article-title":"Systematic review with a meta-analysis: clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients","volume":"9","author":"Wan","year":"2019","journal-title":"BMJ Open"},{"key":"R39-20260812","doi-asserted-by":"crossref","first-page":"106367","DOI":"10.1016\/j.cct.2021.106367","article-title":"SACRED: effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: statins and cirrhosis: reducing events of decompensation","volume":"104","author":"Kaplan","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"R40-20260812","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2025.6135","article-title":"Simvastatin and rifaximin for patients with decompensated cirrhosis","volume":"334","author":"Agarwal","year":"2025","journal-title":"JAMA"},{"key":"R41-20260812","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","article-title":"Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation","volume":"23","author":"Guo","year":"2024","journal-title":"Mol Cancer"},{"key":"R42-20260812","article-title":"Current concerns and future directions of large language model chatGPT in medicine: a machine-learning-driven global-scale bibliometric analysis","author":"Guo","year":"2025","journal-title":"Int J Surg"},{"key":"R43-20260812","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s44355-025-00049-5","article-title":"Artificial Intelligence-based agents in chronic liver disease: transforming diagnostic and therapeutic workflows through clinical decision-making","volume":"2","author":"Singh","year":"2025","journal-title":"Npj Gut Liver"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:35:40Z","timestamp":1786545340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005302","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"2025-10-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}